

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

Alectinib compared with chemotherapy in previously treated patients with ALK-positive NSCLC (ALUR)

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Trial Status
Completed

Trial Runs In
15 Countries

Trial Identifier
NCT02604342 2015-000634-29
MO29750

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized active-controlled multicenter Phase III open-label study will evaluate and compare between treatment groups the efficacy of alectinib versus chemotherapy in participants with ALK-positive advanced NSCLC who were previously treated with chemotherapy and crizotinib, as measured by investigator-assessed progression-free survival (PFS) and to evaluate and compare between treatment groups the central nervous system (CNS) objective response rate (C-ORR) in participants with measurable CNS metastases at baseline, as assessed by an Independent Review Committee (IRC).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02604342 2015-000634-29 MO29750
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
